EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exploring synergy between azole antifungal drugs and statins for Candida auris

Catriona Halliday, Hannah Yejin Kim iD, Enoch Tay, Sharon C A Chen, Jan-Willem Alffenaar iD

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Catriona Halliday und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pat…. Hauptthemen laut MEDLINE: Antifungal Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The University of Sydney Infectious Diseases Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Global emergence of rapidly developing resistance to multiple antifungal drugs and high mortality pose challenges to the treatment of invasive Candida auris infections. New therapeutic approaches are needed, such as repurposing drugs including combination with antifungals. Statins have been reported to exert antifungal effects against various Candida species.

Objectives

Our study investigated potential synergy between the statins (rosuvastatin and fluvastatin) and azoles (voriconazole, posaconazole and isavuconazole) on clinical isolates of C. auris.

Methods

Twenty-one clinical isolates of C. auris were obtained. Chequerboard assays based on the CLSI broth microdilution method were used to assess synergy based on FIC index (FICI) calculations of MICs of individual drugs and in combinations.

Results

Single drug geometric mean (GM) MICs of fluvastatin and rosuvastatin were ≥128 mg/L in all 21 isolates. GM (range) MICs of posaconazole, voriconazole and isavuconazole were 0.259 (0.016–1 mg/L), 0.469 (0.016–2 mg/L) and 0.085 (0.004–1 mg/L), respectively. Combination of azoles with fluvastatin showed synergy in 70%–90% of C. auris isolates. In particular, voriconazole/fluvastatin resulted in 16-fold reduction in voriconazole MIC and synergy in 14/21 (67%) isolates. Posaconazole/fluvastatin resulted in 8-fold reduction in posaconazole MIC and synergy in 19/21 (90%) isolates. Combining rosuvastatin with the azoles also showed synergy against C. auris in 40%–60% of the isolates and additive effect in 40%–50%. None of the combinations was antagonistic.

Conclusions

Our results provide a rationale for pursuing in vivo synergy tests as well as clinical studies to explore tolerability, treatment outcomes, optimal dose and exposure targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsDrug Resistance, FungalVoriconazoleRosuvastatin CalciumMicrobial Sensitivity TestsAzolesFluvastatinCandida aurisNitrilesPyridinesTriazolesCandidiasis

Substanzen

Antifungal AgentsVoriconazoleHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumAzolesFluvastatinisavuconazoleNitrilesPyridinesTriazoles

Autor:innen und Institutionen

  • Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Westmead, NSW, Australia.
  • Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, A15 Science Rd, Camperdown, NSW 2006, Australia.
  • Department of Pharmacy, Westmead Hospital, Westmead, NSW, Australia.
  • The University of Sydney Infectious Diseases Institute (Sydney ID), Westmead, NSW, Australia.
  • Research Education Network, Western Sydney Local Health District, Westmead Hospital, Westmead, NSW, Australia.
  • Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.

ORCID-Profile: Hannah Yejin Kim, Jan-Willem Alffenaar

Förderung

  • The University of Sydney Infectious Diseases Institute

Zitieren

APA

Halliday, C., Kim, H. Y., Tay, E., Chen, S. C. A., & Alffenaar, J. W. (2023). Exploring synergy between azole antifungal drugs and statins for Candida auris. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad303

Vancouver

Halliday C, Kim HY, Tay E, Chen SCA, Alffenaar JW. Exploring synergy between azole antifungal drugs and statins for Candida auris. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad303

BibTeX
@article{Halliday2023,
  author = {Halliday, Catriona and Kim, Hannah Yejin and Tay, Enoch and Chen, Sharon C A and Alffenaar, Jan-Willem},
  title = {Exploring synergy between azole antifungal drugs and statins for Candida auris},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad303}
}
Kostenlos starten →